Evaluation of Decreased Usage of Betablockers After Myocardial Infarction in the SWEDEHEART Registry (REDUCE-SWEDEHEART)

• Status: Recruiting
• Trial end date: 2025-08-31
• Target enrollment: 0
• Participant gender: All

Summary

Long-term beta-blocker therapy has not been investigated in contemporary randomized clinical trials in patients with myocardial infarction and normal heart function. The aim of this study is to determine whether long-term treatment with oral beta-blockade in patients with myocardial infarction and preserved left ventricular systolic ejection fraction reduces the composite of death of any cause or new myocardial infarction..

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Karolinska Institutet
• Collaborators: The Swedish Research Council; Uppsala University
• Treatments: Adrenergic beta-Antagonists; Bisoprolol; Metoprolol

Criteria

Inclusion Criteria:

1. Age≥18 years.

2. Day 1-7 after MI as defined by the universal definition of MI, type 1, included in the SWEDEHEART registry.

3. Undergone coronary angiography during hospitalization.

4. Obstructive coronary artery disease documented by coronary angiography, i.e. stenosis ≥ 50 %, FFR ≤ 0.80 or iFR ≤ 0.89 in any segment at any time point before randomization.

5. Echocardiography performed after the MI showing a normal ejection fraction (EF≥50%).

6. Written informed consent obtained.

Exclusion Criteria:

1. Any condition that may influence the patient's ability to comply with study protocol.

2. Contraindications for beta-blockade

3. Indication for beta-blockade other than as secondary prevention according to the treating physician.